ZA200804868B - Anti-OX40L antibodies and methods using same - Google Patents

Anti-OX40L antibodies and methods using same

Info

Publication number: ZA200804868B
Authority: ZA; South Africa
Prior art keywords: methods; same; ox40l antibodies; ox40l; antibodies
Prior art date: 2005-12-16

Application number

ZA200804868A

Other languages

English (en)

Inventor

Martin Flavius

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-16

Filing date

2006-12-15

Publication date

2009-10-28

2006-12-15 Application filed by Genentech Inc filed Critical Genentech Inc

2009-10-28 Publication of ZA200804868B publication Critical patent/ZA200804868B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

ZA200804868A 2005-12-16 2006-12-15 Anti-OX40L antibodies and methods using same ZA200804868B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US75137705P	2005-12-16	2005-12-16

Publications (1)

Publication Number	Publication Date
ZA200804868B true ZA200804868B (en)	2009-10-28

Family

ID=38616368

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200804868A ZA200804868B (en)	2005-12-16	2006-12-15	Anti-OX40L antibodies and methods using same

Country Status (18)

Country	Link
US (2)	US7812133B2 (es)
EP (1)	EP1973949A2 (es)
JP (1)	JP2009519718A (es)
KR (1)	KR20080080639A (es)
CN (1)	CN101374865A (es)
AR (1)	AR057253A1 (es)
AU (1)	AU2006343459A1 (es)
BR (1)	BRPI0621065A2 (es)
CA (1)	CA2633602A1 (es)
CR (1)	CR10069A (es)
EC (1)	ECSP088543A (es)
IL (1)	IL191820A0 (es)
MA (1)	MA30153B1 (es)
NO (1)	NO20083147L (es)
RU (1)	RU2426744C2 (es)
TW (1)	TW200732349A (es)
WO (1)	WO2007133290A2 (es)
ZA (1)	ZA200804868B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7291331B1 (en)	2002-09-11	2007-11-06	La Jolla Institute For Allergy And Immunology	Methods of treating OX40 medicated recall immune responses
WO2008094297A2 (en)	2006-07-14	2008-08-07	Fei Company	A multi-source plasma focused ion beam system
CN101668776A (zh) *	2007-02-27	2010-03-10	健泰科生物技术公司	拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途
US20090309617A1 (en) *	2007-08-24	2009-12-17	Ye Fang	Biosensor antibody functional mapping
WO2009141239A1 (en) *	2008-05-20	2009-11-26	F. Hoffmann-La Roche Ag	A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US8518405B2 (en) *	2009-10-08	2013-08-27	The University Of North Carolina At Charlotte	Tumor specific antibodies and uses therefor
WO2011073180A1 (en)	2009-12-14	2011-06-23	Ablynx N.V.	Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2012015696A1 (en) *	2010-07-26	2012-02-02	Baylor Research Institute	Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer
EA031849B1 (ru)	2010-08-23	2019-03-29	Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем	Антитела к ox40 и способы их применения
US9845362B2 (en)	2010-10-08	2017-12-19	The University Of North Carolina At Charlotte	Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
MA35035B1 (fr)	2011-04-21	2014-04-03	Bristol Myers Squibb Co	Anticorps polypeptidiques qui antagonisent les cd40
CN103946238B (zh) *	2011-08-23	2016-10-12	德克萨斯州立大学董事会	抗ox40抗体及使用其的方法
CN105744944B (zh)	2013-09-09	2020-07-07	卡尼姆盖德治疗学公司	免疫系统调节器
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
JP2017165652A (ja) *	2014-06-30	2017-09-21	国立大学法人東北大学	新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬
CN107074951B (zh) *	2014-08-04	2021-08-03	贝勒研究院	拮抗性抗-ox40l抗体及其使用方法
US11554181B2 (en)	2014-09-05	2023-01-17	The University Of North Carolina At Charlotte	Tumor specific antibody conjugates and uses therefor
US9512229B2 (en)	2015-03-03	2016-12-06	Kymab Limited	Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9139653B1 (en)	2015-04-30	2015-09-22	Kymab Limited	Anti-human OX40L antibodies and methods of treatment
DE112016001013T5 (de) *	2015-03-03	2017-12-21	Kymab Limited	Antikörper, verwendungen und verfahren
US9434785B1 (en)	2015-04-30	2016-09-06	Kymab Limited	Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
DK3265117T3 (da)	2015-03-06	2021-02-08	Canimguide Therapeutics Ab	Immunsystemmodulatorer og præparater
CN115109158A (zh)	2015-05-07	2022-09-27	阿吉纳斯公司	抗ox40抗体及其使用方法
CA3007233A1 (en)	2015-12-02	2017-06-08	Agenus Inc.	Antibodies and methods of use thereof
DE102016105069A1 (de)	2016-03-18	2017-09-21	Eberhard Karls Universität Tübingen Medizinische Fakultät	Antivirale Immuntherapie durch Membranrezeptorligation
EP3443984A4 (en) *	2016-04-15	2019-04-10	Pontificia Universidad Católica De Chile	PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND THE SERIOUS DEGREE OF RESPIRATORY INFECTION BY human metapneumovirus (hMPV) WITH AT LEAST ONE FUNCTION OF TSLP- AND / OR TSLPR- AND / OR OX40L- AND / OR CD177-MOLECULE neutralizing agent AND PHARMACEUTICAL ACCEPTABLE ALTERNATIVE FUEL AND USE THEREOF
EP3471754A1 (en)	2016-06-20	2019-04-24	Kymab Limited	Anti-pd-l1 antibodies
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
KR102604433B1 (ko)	2016-08-09	2023-11-24	키맵 리미티드	항-icos 항체
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538152A4 (en)	2016-11-09	2020-09-30	Agenus Inc.	ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
GB201709808D0 (en)	2017-06-20	2017-08-02	Kymab Ltd	Antibodies
WO2019100320A1 (en)	2017-11-24	2019-05-31	Eucure (Beijing) Biopharma Co., Ltd	Anti-ox40 antibodies and uses thereof
WO2019122882A1 (en)	2017-12-19	2019-06-27	Kymab Limited	Bispecific antibody for icos and pd-l1
GB202012331D0 (en) *	2020-08-07	2020-09-23	Petmedix Ltd	Therapeutic antibodies
CN114437228B (zh) *	2020-10-30	2024-02-06	中国科学院生物物理研究所	一种il-2与抗体亚单位构成的双功能融合蛋白
IL310701A (en) *	2021-08-10	2024-04-01	Kymab Ltd	Treatment of atopic dermatitis
AU2023219227A1 (en) *	2022-02-09	2024-08-01	Petmedix Ltd	Therapeutic antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5457035A (en) *	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
US5821332A (en)	1993-11-03	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) *	1994-02-10	2001-06-05	Board Of Trustees Of The Leland Stanford Junior University	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) *	1997-09-25	2007-05-16	武田薬品工業株式会社	ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
CA2410188A1 (en) *	2000-06-06	2001-12-13	Idec Pharmaceutical Corporation	Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
FR2822846B1 (fr) *	2001-04-03	2004-01-23	Technopharm	Procede de preparation et de selection d'anticorps
GB0123276D0 (en)	2001-09-27	2001-11-21	Imp College Innovations Ltd	Uses of agents that bind immune-system components
JP3926596B2 (ja)	2001-09-28	2007-06-06	独立行政法人科学技術振興機構	Ｏｘ４０ｌ遺伝子を導入した自己免疫疾患モデル非ヒト哺乳動物
WO2003059245A2 (en)	2001-12-18	2003-07-24	J & J Research Pty Ltd	Method of treating asthma
IL164376A0 (en)	2002-04-03	2005-12-18	Applied Research Systems	Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2004019866A2 (en)	2002-08-28	2004-03-11	Immunex Corporation	Compositions and methods for treating cardiovascular disease
US7291331B1 (en)	2002-09-11	2007-11-06	La Jolla Institute For Allergy And Immunology	Methods of treating OX40 medicated recall immune responses
AU2005229009A1 (en) *	2004-03-23	2005-10-13	Amgen, Inc.	Monoclonal antibodies specific for human OX40L (CD 134L)
JP2006081061A (ja) *	2004-09-13	2006-03-23	Alpine Electronics Inc	音声出力装置及び音声／映像出力装置
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
CN101668776A (zh)	2007-02-27	2010-03-10	健泰科生物技术公司	拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途

2006
- 2006-12-15 EP EP06851330A patent/EP1973949A2/en not_active Withdrawn
- 2006-12-15 CN CNA2006800529729A patent/CN101374865A/zh active Pending
- 2006-12-15 JP JP2008545995A patent/JP2009519718A/ja not_active Withdrawn
- 2006-12-15 AU AU2006343459A patent/AU2006343459A1/en not_active Abandoned
- 2006-12-15 KR KR1020087017186A patent/KR20080080639A/ko not_active Application Discontinuation
- 2006-12-15 CA CA002633602A patent/CA2633602A1/en not_active Abandoned
- 2006-12-15 WO PCT/US2006/062173 patent/WO2007133290A2/en active Application Filing
- 2006-12-15 AR ARP060105564A patent/AR057253A1/es not_active Application Discontinuation
- 2006-12-15 BR BRPI0621065-1A patent/BRPI0621065A2/pt not_active IP Right Cessation
- 2006-12-15 US US12/097,733 patent/US7812133B2/en active Active
- 2006-12-15 ZA ZA200804868A patent/ZA200804868B/xx unknown
- 2006-12-15 TW TW095147231A patent/TW200732349A/zh unknown
- 2006-12-15 RU RU2008129111/10A patent/RU2426744C2/ru not_active IP Right Cessation
2008
- 2008-05-29 IL IL191820A patent/IL191820A0/en unknown
- 2008-06-12 CR CR10069A patent/CR10069A/es not_active Application Discontinuation
- 2008-06-13 EC EC2008008543A patent/ECSP088543A/es unknown
- 2008-07-11 MA MA31104A patent/MA30153B1/fr unknown
- 2008-07-15 NO NO20083147A patent/NO20083147L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,748 patent/US20100272738A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2007133290A8 (en)	2008-03-27
KR20080080639A (ko)	2008-09-04
CN101374865A (zh)	2009-02-25
ECSP088543A (es)	2008-07-30
IL191820A0 (en)	2008-12-29
US7812133B2 (en)	2010-10-12
AR057253A1 (es)	2007-11-21
NO20083147L (no)	2008-09-16
AU2006343459A1 (en)	2007-11-22
RU2426744C2 (ru)	2011-08-20
WO2007133290A3 (en)	2008-01-10
RU2008129111A (ru)	2010-01-27
CA2633602A1 (en)	2007-11-22
US20090053230A1 (en)	2009-02-26
BRPI0621065A2 (pt)	2011-11-29
EP1973949A2 (en)	2008-10-01
JP2009519718A (ja)	2009-05-21
CR10069A (es)	2008-10-10
MA30153B1 (fr)	2009-01-02
US20100272738A1 (en)	2010-10-28
TW200732349A (en)	2007-09-01
WO2007133290A2 (en)	2007-11-22

Publication	Publication Date	Title
IL272883A (en)	2020-04-30	Monoclonal antibodies and their uses
IL191820A0 (en)	2008-12-29	Anti-ox40l antibodies and methods using same
IL222922A (en)	2015-07-30	Antibodies against neurophilin-1 and their use
ZA200805741B (en)	2009-10-28	Anti-MN antibodies and methods of using same
PT1973950E (pt)	2014-12-29	Anticorpos anti-epbh4 e métodos que os utilizam
AP2008004471A0 (en)	2008-06-30	Anti-Alpha2 Intergin antibodies and their uses
IL184024A0 (en)	2008-12-29	Irta-5 antibodies and their uses
IL182554A0 (en)	2007-09-20	Anti-addl antibodies and uses thereof
ZA200608100B (en)	2009-09-30	IRTA-5 antibodies and their uses
PT2343320T (pt)	2018-01-23	Anticorpos anti-gitr e as suas utilizações
IL187710A0 (en)	2008-08-07	Anti-trkb monoclonal antibodies and uses thereof
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
IL178838A0 (en)	2007-03-08	Antibodies
EP1846032A4 (en)	2009-01-28	LUCA2 AND ANTIBODY BINDING
HK1107402A1 (en)	2008-04-03	Kid31 and antibodies that bind thereto kid31
IL231891A (en)	2016-10-31	Anti-ephrinb2 antibodies and methods for their use
ZA200703406B (en)	2009-08-26	Anti-ADDL antibodies and uses thereof
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
ZA200806053B (en)	2009-12-30	Anti-EphB4 antibodies and methods using same
ZA200702281B (en)	2009-08-26	IRTA-4 antibodies and their uses
GB0505620D0 (en)	2005-04-27	Methods and materials therefor
ZA200705716B (en)	2008-11-26	IRTA-2 antibodies and their uses
GB0507272D0 (en)	2005-05-18	Antibody and uses thereof
GB0507219D0 (en)	2005-05-18	Antibody and uses thereof
GB0518875D0 (en)	2005-10-26	Methods and means